Lucid Diagnostics Inc (NASDAQ:LUCD) shares, rose in value on Wednesday, July 09, with the stock price up by 5.66% to the previous day’s close as strong demand from buyers drove the stock to $1.12.
Actively observing the price movement in the last trading, the stock closed the session at $1.06, falling within a range of $1.05 and $1.12. The value of beta (5-year monthly) was 1.316. Referring to stock’s 52-week performance, its high was $1.80, and the low was $0.72. On the whole, LUCD has fluctuated by -13.18% over the past month.
With the market capitalization of Lucid Diagnostics Inc currently standing at about $121.18 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-13.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LUCD’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a Hold.
The stock’s technical analysis shows that the price of LUCD currently trading nearly -5.25% and -10.17% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 42.71, while the 7-day volatility ratio is showing 6.84% which for the 30-day chart, stands at 6.16%. Furthermore, Lucid Diagnostics Inc (LUCD)’s beta value is 1.23.
A comparison of Lucid Diagnostics Inc (LUCD) with its peers suggests the former has fared considerably weaker in the market. LUCD showed an intraday change of 5.66% in last session, and over the past year, it grew by 36.80%%.
Data on historical trading for Lucid Diagnostics Inc (NASDAQ:LUCD) indicates that the trading volumes over the past 10 days have averaged 1.93 and over the past 3 months, they’ve averaged 1.36 million. According to company’s latest data on outstanding shares, there are 84.37 million shares outstanding.
Nearly 62.71% of Lucid Diagnostics Inc’s shares belong to company insiders and institutional investors own 9.89% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.66 million shares as on 2025-06-13, resulting in a short ratio of 1.38. According to the data, the short interest in Lucid Diagnostics Inc (LUCD) stood at 231.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 1.78 million. The stock has risen by 41.95% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LUCD stock heading into the next quarter.
